TROAP: A Potential Drug Target and Biomarker (G10024)

Target Name: TROAP

NCBI ID: G10024

TROAP

TROAP: A Potential Drug Target and Biomarker

TROAP (Tumor Receptor Open Access Program) is a protein that is expressed in various types of cancer cells, including breast, lung, and ovarian cancer. It is a transmembrane glycoprotein that consists of an extracellular portion and an intracellular portion. The intracellular portion of TROAP contains a unique N-terminus that is involved in several signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established oncogenic pathway that is involved in the regulation of cell growth, differentiation, and survival. It is a complex signaling pathway that is activated by various growth factors, including TGF-β1, which is a potentoncogenic transcription factor that plays a central role in the development of cancer.

TROAP is a potential drug target because it is involved in the TGF-β pathway and has been shown to be a good candidate for inhibition. In fact, several studies have shown that inhibition of TROAP has anti-tumor effects in various cancer models.

One of the advantages of TROAP as a drug target is its expression in various types of cancer cells. This makes it a promising candidate for targeting cancer cells that are resistant to traditional cancer treatments. In addition, TROAP is also expressed in normal cells, which means that it is potential to target cancer without causing toxicity to the normal cells.

Another advantage of TROAP is its involvement in the regulation of cell survival. Studies have shown that TROAP is involved in the regulation of cell survival by promoting the expression of the anti-apoptotic protein Bcl-2. Bcl-2 is a protein that protects cells from programmed cell death, and its expression is often associated with cancer cell survival.

In addition, TROAP is also involved in the regulation of cell growth. Studies have shown that TROAP is involved in the regulation of cell growth by promoting the expression of the cell growth factor PDGF-2. PDGF-2 is a potentoncogenic protein that plays a central role in the development of cancer.

Overall, TROAP is a promising drug target because of its involvement in the TGF-β pathway and its potential to target cancer cells that are resistant to traditional cancer treatments. Further research is needed to fully understand the anti-tumor effects of TROAP and to develop safe and effective therapies that target this protein.

Protein Name: Trophinin Associated Protein

Functions: Could be involved with bystin and trophinin in a cell adhesion molecule complex that mediates an initial attachment of the blastocyst to uterine epithelial cells at the time of the embryo implantation

The "TROAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TROAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets